
	Reporting Unit
	Diagnostics		Collection Devices		Total
Balance at January 1, 2024	$	—	$	35,696	$	35,696
Acquisition	6,388		—		6,388
Change related to foreign currency translation	—		(1,754)		(1,754)
Balance at December 31, 2024	6,388		33,942		40,330
Acquisition	1,775		—		1,775
Change related to foreign currency translation	—		1,258		1,258
Balance at December 31, 2025	$	8,163	$	35,200	$	43,363

On November 30, 2025, the Company performed its quantitative annual goodwill impairment test. The Company utilizes a combination of the income approach and market approach in determining the fair value of its two reporting units. The test concluded that the carrying value of the Company's reporting units was below fair value indicating there was no impairment of goodwill.


		December 31, 2025
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	9,134	$	(9,134)	$	—
Patents and product rights	5	7,596		(7,596)		—
Developed technology	7-15	8,995		(7,095)		1,900
Trade names	5-15	3,501		(3,355)		146
		29,226		(27,180)		2,046
Indefinite Life Intangible Assets
IPR&D technology (Note 13)	N/A	17,000		—		17,000
		$	46,226	(27,180)		19,046


		December 31, 2024
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	10,858	$	(10,858)	$	—
Patents and product rights	5	7,495		(7,399)		96
Developed technology	7-10	10,169		(10,169)		—
Trade names	5-15	4,327		(3,988)		339
		32,848		(32,413)		435
Indefinite Life Intangible Assets
IPR&D technology (Note 13)	N/A	17,000		—		17,000
		$	49,848	$	(32,413)	$	17,435

During 2023, the Company identified a triggering event to test for the recoverability of intangible assets given the decline in the Company's market capitalization leading up to and as of its annual goodwill impairment testing date. The Company performed an undiscounted cash flow analysis and determined the carrying value of the developed technology, trade names, and customer relationships intangible assets could not be recovered through the sum of the undiscounted future

cash flows. The Company used an income approach to determine the fair value of the developed technology and customer relationships intangible assets and the relief from royalty method for the trade names. As a result of this analysis, the Company determined the intangible assets associated with Diversigen and Novosanis were impaired as the fair value of the developed technology, trade names, and customer relationships did not exceed their carrying value. The Company recognized a pre-tax impairment charge of $6.2 million during the year ended December 31, 2023, which is reported in loss on impairments in the Company's consolidated statement of operations.

Also in 2023, the Company determined that its remaining developed technology intangible asset was fully impaired. As a result of failed stability studies, the Company decided to no longer pursue the technology. The Company recognized a pre-tax impairment charge of $2.4 million during the year ended December 31, 2023 which is reported in loss on impairments in the Company's consolidated statement of operations.